entertainment -WSS

entertainment

author：Wikipedia 2025-09-27 20:43:43 - browse：84461

The Food and Drug Administration on Friday approved a new, rapid-acting medicine made by Sage Therapeutics to treat postpartum depression, the first oral treatment for the condition. But the agency denied the company’s application for an indication for major depression, a much larger potential market.

The drug, which will be sold under the brand name Zurzuvae, is not meant to be taken chronically. Patients take it orally for 14 days. In two clinical trials, the drug was found to significantly improve depressive symptoms more than a placebo. The effect was maintained for four weeks after treatment.

“Maternal mental health has been sidelined for far too long, but today’s approval of Zurzuvae helps to change that. Women have been waiting for an oral medicine that can specifically and rapidly improve the symptoms of PPD and we are proud to be able to deliver that,” said Barry Greene, Sage’s CEO, in a press release.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： STAT's guide to the next generation of CAR

leisure time

WSS

The strategy behind pharma's lawsuits over drug pricing reform

UnitedHealth’s Optum accused of antitrust violations in California

3 hurdles to bringing medical devices to the U.S. market

Disclosing genetic information: not as worrisome as once feared

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Fetal surgery at risk from Dobbs and new abortion restrictions

explore

entertainment

focus

Tori Bowie and the unacceptable rates of Black maternal death

ReNAgade cuts staff seven months after raising $300 million

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Takeda, Janssen join wearable maker to measure scratching

Novavax promises a turnaround & Lilly roils the obesity market

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Apple is now the first public company to be valued at $3 trillion

The EPA's new lead rule: How one expert crunched the numbers

Duchenne breakthrough therapy leaves behind pioneering families

UnitedHealth’s Optum accused of antitrust violations in California

focus

New guidelines on severe brain injury complicate already difficult decisions

Diagnostic tests are hitting their mathematical limits

Diagnostic tests are hitting their mathematical limits

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

FDA investigates CAR

focus

hotspot

leisure time

entertainment